8-K: MIRA Pharmaceuticals Announces Positive Preclinical Results for Ketamir-2 in Diabetic Neuropathy Model

MIRA Pharmaceuticals reports positive preclinical study results for its oral ketamine analog, Ketamir-2, showing significant reduction in neuropathic pain symptoms in a rat model of diabetic neuropathy.

Summary

• MIRA Pharmaceuticals announced positive preclinical results for Ketamir-2 in a rat model of diabetic neuropathy.
• The study used a rat model of type 2 diabetes to induce insulin resistance, hyperglycemia, and reduced pancreatic function.
• By week 8, the animals developed neuropathic pain, which was confirmed through mechanical hypersensitivity assessments.
• Animals treated with Ketamir-2 showed a statistically significant reduction in neuropathic pain symptoms compared to controls.
• A subset of treated animals returned to pre-diabetic baseline sensitivity levels, indicating full symptom resolution.
• These results support the potential of Ketamir-2 to reverse pain-related hypersensitivity in diabetic neuropathy.
• The findings reinforce prior preclinical results demonstrating Ketamir-2's efficacy, oral bioavailability, and non-dissociative profile.
• MIRA plans to initiate a Phase IIa trial in diabetic neuropathy patients by the end of 2025.

Sentiment

Score: 8

Explanation: The announcement of positive preclinical results is a strong positive indicator for the company's drug development program, justifying a high sentiment score.

Positives

• Ketamir-2 showed a statistically significant reduction in neuropathic pain symptoms.
• Some animals experienced full symptom resolution, returning to pre-diabetic baseline sensitivity levels.
• The study reinforces Ketamir-2's efficacy, oral bioavailability, and non-dissociative profile.

Future Outlook

MIRA plans to initiate a Phase IIa trial in diabetic neuropathy patients by the end of 2025.

Industry Context

The development of non-opioid treatments for diabetic neuropathy is a significant area of unmet medical need, and positive preclinical results for Ketamir-2 could position MIRA Pharmaceuticals favorably in this market.

Stakeholder Impact

• Positive results could increase shareholder value.
• Successful clinical trials could lead to a new treatment option for patients with diabetic neuropathy.

Next Steps

• Initiation of Phase IIa trial in diabetic neuropathy patients by the end of 2025.

Key Dates

Keywords

Ketamir-2, diabetic neuropathy, MIRA Pharmaceuticals, preclinical study, neuropathic pain, clinical trial, pharmaceuticals